Focus:
University of Cambridge spin out PolyProx Therapeutics has announced it has raised £3.4m of seed capital, led by Cambridge Innovation Capital (CIC), RT Capital and Cambridge Enterprise.
The top ten orphan drugs in oncology accounted for approximately $54.1bn in net sales in 2018, with just three of Roche’s drugs Herceptin, Avastin and Rituxan collectively accounting for approximately...
AstraZeneca and MSD have received a positive opinion for Lynparza (olaparib) as a first-line maintenance treatment of BRCA-mutated advanced ovarian cancer.
China-headquartered antibody engineering company Adagene and Swiss oncology-focused ADC Therapeutics have announced they have entered into a drug discovery collaboration and license agreement.
Creative Pharma Services attended the Hellenic Society for Pharmaceutical Management on 18 April.
The University of Southampton’s Centre of Cancer Immunology is situated at Southampton General Hospital.
Common symptoms associated with multiple myeloma include bone pain, nausea and constipation.
Pfizer has partnered with patient-centred research firm Concerto HealthAI to fast-track actionable patient insights for investigational and commercialised cancer therapies.
Roche is trying to carve out a therapeutic niche within the breast cancer market through the novel combinations of targeted agents.
PARP inhibitors are positioned to play a transformative role in the treatment of a subset of pancreatic cancer patients.
